Literature DB >> 17505415

Epidermal growth factor receptor gene mutations in early pulmonary adenocarcinomas.

Haruhiko Nakamura1, Norihito Kawasaki, Masahiko Taguchi, Harubumi Kato.   

Abstract

BACKGROUND: Epidermal growth factor receptor (EGFR) gene mutations are frequently found in pulmonary adenocarcinomas.
MATERIALS AND METHODS: Various lung cancers (n=30) including 8 small adenocarcinomas were examined for EGFR gene mutations in three exons.
RESULTS: Mutations were detected in 32% of adenocarcinomas. Exon 19 mutations were detected in 5 tumors, often advanced stages: 1 in Noguchi's pathologic type C, 2 in type D, and 2 in type F. Exon 21 mutations were detected in 3 tumors, all small adenocarcinomas in type C, at pathologic stage IA.
CONCLUSION: We suspect that exon 21 mutations are early events in small bronchioloalveolar carcinomas, while exon 19 mutations are later events occurring in adenocarcinomas of various types.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17505415

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  3 in total

1.  Ground-glass opacities showing an adenoma-to-carcinoma sequence in the lung.

Authors:  Haruhiko Nakamura; Takeshi Hirata; Masahiko Taguchi; Hajime Kitamura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-08-13

2.  Targeted next-generation sequencing for analyzing the genetic alterations in atypical adenomatous hyperplasia and adenocarcinoma in situ.

Authors:  Xuan Xu; Na Li; Ruiying Zhao; Lei Zhu; Jinchen Shao; Jie Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-18       Impact factor: 4.553

3.  Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice.

Authors:  Albrecht Stenzinger; Jörn Sträter; Martin Faehling; Birgit Schwenk; Sebastian Kramberg; Robert Eckert; Anna-Lena Volckmar
Journal:  Oncotarget       Date:  2017-09-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.